Business Wire

CA-ENCHROMA

25.10.2021 14:02:10 CEST | Business Wire | Press release

Share
Study Finds Overwhelming Evidence That Color Blindness Hinders Learning in School, Reports EnChroma

EnChroma – creators of glasses for color blindness – today released the results of a landmark study that clearly demonstrates the negative effect color blindness has on learning for millions of students. The data strongly indicates that schools are failing to identify color blind students and that parents, educators and legislators need to better support these students.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005173/en/

In early 2020, nearly 1,000 color blind people, including the parents of color blind children, shared their opinions about how Color Vision Deficiency (CVD) affected their educational experiences. Seventy-eight percent said they were often frustrated or confused by colors in school assignments and activities. One in three say color blindness affected their confidence in school, and 30% felt like they might be a “slow learner” before discovering they’re color blind.

A contributing factor is the lack of testing for color blindness in schools. According to EnChroma, only 11 of 50 states test for CVD. As a result, many students do not realize they’re color blind. In fact, nearly half of color blind people said they didn’t learn they’re color blind until after 7th grade, almost one in three while in high school or later, and one in five don’t find out until after high school or college.

“The evidence is overwhelming that color blindness creates learning challenges for color blind students and that parents, educators, and politicians must become more aware of the prevalence of color vision deficiency, and its impact, and take action,” said Erik Ritchie, CEO of EnChroma. “Too many kids go deep into their educations without the student, their parents or teachers knowing they’re color blind. Testing for color blindness has to become universal in schools in all states and countries, and learning materials adapted to accommodate and create a level playing field for CVD students.”

One in 12 men (8%) and one in 200 women (.5%) are color blind – 13 million in the US, 30 million in Europe, and 350 million worldwide. For them, understanding colorful information in school, at work and in daily life can cause obstacles. While people with normal color vision see over one million shades of color, the color blind only see an estimated 10% of hues and shades. Common color confusions include green and yellow, gray and pink, purple and blue, and red and brown, with colors appearing muted and dull. Since 80% of information is conveyed visually, this creates issues for color blind students.

Numerous renowned universities plan to offer EnChroma glasses to color blind students to borrow on their campuses, and to educate staff to adapt materials to accommodate CVD students. They include Boston University, North Carolina State University, Alfred University and Francis Marion University, with others joining soon.

Click here for more images of how the color blind see colors.

“A teacher discovered I was color blind in the third grade. Up to that point I was often referred to as “stupid” because I couldn’t color primary colors correctly,” said one color blind survey respondent. Another relayed: “I was unable to pass chromatography lessons in organic chemistry because I couldn't distinguish the colors accurately. I had to drop the class and eventually change majors.”

Highlights from the EnChroma survey include:

  • Four out of ten color blind students try to avoid schoolwork and activities involving color, and nearly half are less interested in painting, drawing, nature walks and field trips to art museums
  • More than 1 in three color blind people say teachers got frustrated with them when they couldn’t understand schoolwork involving color
  • Only one in four parents tell teachers that their child is color blind, and only 20% of teachers adapt schoolwork to accommodate color vision deficient students
  • 81% believe teachers should adapt teaching materials for color blind students
  • 87% support mandatory testing of schoolchildren for color vision deficiency
  • One in four were teased by classmates or teachers due to being color blind
  • Two of three parents worry about color blindness affecting their child’s education

EnChroma encourages schools to quickly and easily test students in under two minutes for color blindness via our free online test available here and at enchroma.com . To read comments from color blind respondents about their educational experiences click here .

EnChroma Color Accessibility Program

EnChroma is the lead advocate for “color accessibility” through its EnChroma Color Accessibility Program . The program helps public venues, schools, state parks, libraries, museums, and other organizations purchase and loan EnChroma glasses to color blind students and guests to help make schoolwork that involves color, colorful exhibits, attractions and/or experiences accessible to the CVD. In addition to our free color blindness test, EnChroma also offers materials for schools to share with teachers, parents and students to educate them about color blindness, its effects, and how to support color blind students. EnChroma offers a similar program for employers.

EnChroma glasses are engineered with special optical filters that help the color blind see an expanded range of colors more vibrantly, clearly and distinctly. A recent study by the University of California, Davis, and France’s INSERM Stem Cell and Brain Research Institute , demonstrated the effectiveness of EnChroma glasses.

Media: Product shots, images and interactive GIFs illustrating the challenges to learning for those with color vision deficiencies can be downloaded here. EnChroma’s CEO, survey respondents, and university and K-12 educators and parents, are available for interviews. Of the nearly 1,000 respondents to the survey, nearly three-fourths are color blind (740) and the other 247 the parents of color blind children.

About EnChroma

Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance . For more information call 510-497-0048 or visit enchroma.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/enchroma/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye